Bristol Myers Squibb (CELG-RI) Curent Deferred Tax Liability (2009 - 2012)
Bristol Myers Squibb (CELG-RI) posted quarterly Curent Deferred Tax Liability of -$10.0 million for Q4 2012, down 66.67% year-over-year from -$30.0 million in Q1 2012, and down 66.67% quarter-over-quarter from -$6.0 million in Q4 2011.
Bristol Myers Squibb (CELG-RI) Curent Deferred Tax Liability (2009 - 2012) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Curent Deferred Tax Liability for 4 consecutive years, with -$10.0 million the latest figure, recorded in Q4 2012.
- In Q4 2012, Curent Deferred Tax Liability fell 66.67% year-over-year to -$10.0 million; the TTM figure through Dec 2012 stood at -$10.0 million (down 66.67% YoY), while the FY2012 annual figure was -$10.0 million, down 66.67% from the prior year.
- Curent Deferred Tax Liability fell to -$10.0 million in Q4 2012 per CELG-RI's latest filing, from -$6.0 million in the prior quarter.
- Across five years, Curent Deferred Tax Liability topped out at $8.0 million in Q4 2009 and bottomed at -$10.0 million in Q4 2012.
- Historically, Curent Deferred Tax Liability has averaged -$3.2 million across 4 years, with a median of -$5.5 million in 2010.
- Annual changes were most pronounced in 2010 — Curent Deferred Tax Liability plunged 162.5% — and 2011, when it dropped 20.0%.
- Bristol Myers Squibb's Curent Deferred Tax Liability stood at $8.0 million in 2009, then slumped by 162.5% to -$5.0 million in 2010, then slipped by 20.0% to -$6.0 million in 2011, then slumped by 66.67% to -$10.0 million in 2012.
- Business Quant data shows CELG-RI's Curent Deferred Tax Liability at -$10.0 million in Q4 2012, -$6.0 million in Q4 2011, and -$5.0 million in Q4 2010.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax Liability (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -10.00 Mn |
| Dec 31, 2012 | -10.00 Mn |
| Dec 31, 2011 | -6.00 Mn |
| Dec 31, 2011 | -6.00 Mn |
| Dec 31, 2010 | -5.00 Mn |
| Dec 31, 2010 | -5.00 Mn |
| Dec 31, 2009 | 8.00 Mn |
| Dec 31, 2009 | 8.00 Mn |